India's 2026 Healthcare Plan: A Focus on Quality and Innovation
The Indian government is setting its sights on enhancing drug quality and expanding digital health initiatives by 2026, with a strong emphasis on good manufacturing practices. While the pharmaceutical market is poised for significant growth, smaller manufacturers may encounter hurdles in meeting compliance standards and securing necessary capital investments.
India aims to transition from being the 'pharmacy of the world' to a leading global life sciences hub. Achieving this goal presents significant execution challenges, particularly concerning maintaining stringent quality standards and ensuring consistent policy implementation. The government's plan for 2026 mandates enhanced drug quality and the expansion of digital health services, paving the way for a focused five-year execution phase.
Currently, the industry's market size stands at $11 billion, representing 1.5% of the global market, according to 'Invest India'. Projections indicate substantial growth, with expectations reaching $50 billion by 2030.
GMP Compliance and Challenges for Small Manufacturers
Industry experts and stakeholders emphasize that the immediate test of India's commitment lies in implementing revised good manufacturing practices (GMP). These updated standards, aligned with World Health Organization guidelines, will become mandatory for smaller pharmaceutical companies—those with a turnover below ₹250 crore—starting January 1, 2026. Businesses failing to comply risk closure.
Parag Bhatia, director of Laborate Pharmaceuticals, highlights the need for smaller manufacturers to invest in upgraded facilities. According to Bhatia, these essential changes will reduce operational risks, minimize recalls, and ensure consistent product quality. However, concerns remain regarding the financial and technical capabilities of numerous small units in India to meet these requirements.
Dr. Aashish Chaudhry, managing director of Aakash Healthcare Pvt Ltd, emphasizes the critical importance of GMP certification for pharmaceutical companies, comparing it to the necessity of fire compliance certification for hospitals.
Investing in Research and Innovation
The push for enhanced drug quality is paralleled by a significant focus on innovation, underscored by the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme. This initiative allocates a substantial ₹4,200 crore to bolster research and development efforts.
Sudarshan Jain, secretary-general of the Indian Pharmaceutical Alliance, emphasizes that goods and services tax reforms and broader GMP implementation will reinforce India's ambitions. Health tracking apps like Shotlee can help monitor various health metrics during R&D phases, aiding in data collection and analysis.
Jain notes the strong response to the PRIP rollout, calling it a significant beginning for the innovation agenda. He adds that the next 25 years will be defined by innovation, quality, and access, particularly as drugs worth over $300 billion are set to lose exclusivity globally soon.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
The challenge now lies in converting policy signals into tangible R&D investment and output. Himanshu Baid, managing director of Poly Medicure Ltd, urges the government to maintain its policy focus in the med-tech sector, emphasizing the need for the sector to evolve from being a manufacturer to an innovator of advanced med-tech solutions to secure global market share.
Addressing Public Health Concerns
The 2026 health roadmap prioritizes expanding the Ayushman Bharat insurance scheme, scaling up digital health services, and strengthening digital records and telemedicine. However, several critical public health goals are currently off-track.
India bears an estimated 26% of the global tuberculosis (TB) burden. While TB incidence and mortality rates have decreased from 2015 levels, the government has extended its TB elimination target from 2025 to 2030, aligning with the United Nations Sustainable Development Goal (SDG) 3. According to the India TB Report 2024, the country reported 2.6 million new cases and 321,095 deaths in 2023. The National TB Elimination Programme (NTEP) continues to enhance case detection and treatment regimens nationwide.
Obesity has become a significant public health challenge. Research from the Indian Council of Medical Research projects a surge in overweight and obese adults to 449 million by 2050, up from 180 million in 2021.
The recent introduction of weight-loss drugs like semaglutide offers a market-based solution. However, Dr. Chaudhry cautions about the uncertainty of long-term benefits, noting the importance of muscle training and a high-protein diet when taking such drugs.
India is grappling with a severe air pollution crisis. The government has urged states and Union Territories to develop a robust public health response, including establishing specialist clinics in the 131 cities failing to meet ambient air quality standards for five years.
Digital Healthcare Advancements
AI and advanced technology are considered key drivers, according to Bharath Sesha, managing director at Philips for the Indian subcontinent. Integrating and effectively utilizing these technologies across India's healthcare infrastructure will be a considerable logistical challenge.
As healthcare providers adopt generative AI for documentation and diagnostics, the emphasis will be on creating transparent, expert-validated AI systems.
In summary, experts suggest that 2026 will be a pivotal year in which the government must demonstrate its ability to implement its quality agenda while addressing significant public health challenges and funding genuine innovation.
